发明名称 |
RNA aptamers against BAFF-R as cell-type specific delivery agents and methods for their use |
摘要 |
In one embodiment, a B cell specific aptamer-siRNA chimera is provided. The B cell specific aptamer-siRNA chimera may include an RNA aptamer that binds BAFF-R and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. In another embodiment, a B cell specific RNA aptamer is provided. The RNA aptamer may be a molecule that binds to BAFF-R that has the sequence SEQ ID NO:37, SEQ ID NO:38 or SEQ ID NO:39. In some embodiments, the RNA aptamer is conjugated, via a nucleotide linker, to an siRNA molecule that suppresses expression of one or more target oncogenes in one or more B cells. In one aspect, the one or more target oncogenes are selected from Bcl6, Bcl2, STAT3, Cyclin D1, Cyclin E2 and c-myc. In another embodiment, methods for treating a B cell malignancy in a cancer patient are provided. Such methods may include administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific RNA aptamer that binds BAFF-R. |
申请公布号 |
US9353374(B2) |
申请公布日期 |
2016.05.31 |
申请号 |
US201514685486 |
申请日期 |
2015.04.13 |
申请人 |
CITY OF HOPE |
发明人 |
Rossi John;Tiemann Katrin;Zhou Jiehua;Vallazza Britta |
分类号 |
C12N15/11;C12N15/113;C12N15/115;A61K47/48;A61K31/713 |
主分类号 |
C12N15/11 |
代理机构 |
Perkins Coie LLP |
代理人 |
Perkins Coie LLP ;Dueppen Lara |
主权项 |
1. A method for treating a B cell malignancy in a cancer patient comprising administering a therapeutically effective amount of a therapeutic composition, the therapeutic composition comprising a B cell specific aptamer-siRNA chimera comprising an RNA aptamer comprising an RNA molecule having the sequence SEQ ID NO:9, SEQ ID NO:10 or SEQ ID NO:11 that binds BAFF-R, and an siRNA molecule conjugated to the RNA aptamer via a nucleotide linker. |
地址 |
Duarte CA US |